Weekly 24 h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours

European Journal of Cancer

Volumn 41, Issue 10, 2005, Pages 1431-1438

  Schoffski P ^a,c   Breidenbach, I ^a   Krauter, J ^a   Bolte, O ^a   Stadler, M ^a   Ganser, A ^a   Wilhelm Ogunbiyi, K ^b   Lentzen, H ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b VISCUM AG   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aviscumine; CD75s; Phase I study; Recombinant mistletoe lectin; Ribosome inactivating proteins; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; AVISCUMINE; RIBOSOME INACTIVATING PROTEIN; RVISCUMIN; UNCLASSIFIED DRUG; VISCUM ALBUM LECTIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER GROWTH; CANCER PAIN; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPOPROTEINEMIA; INJECTION SITE REACTION; INSOMNIA; KIDNEY FUNCTION; LARYNX EDEMA; LEUKOCYTE COUNT; LIVER FUNCTION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPHIL; NOCTURIA; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE SARCOMA; SOLID TUMOR; SWEATING; TASTE DISORDER; THROMBOCYTOPENIA; URINARY FREQUENCY; URTICARIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PLANT PREPARATIONS; PLANT PROTEINS; RECOMBINANT PROTEINS; TOXINS, BIOLOGICAL;

EID: 20444469180     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.019     Document Type: Article

References (24)

1. T. Hajto, K. Hostanska, and H.J. Gabius Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients Cancer Res 49 1989 4803 4808
2. O. Janssen, A. Scheffler, and D. Kabelitz In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis) Arzneim Forsch 43 1993 1221 1227
3. A. Büssing, K. Suzart, and J. Bergmann Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by mistletoe lectins Cancer Lett 99 1996 59 72
4. K. Hostanska, T. Hajto, and K. Weber A natural immunity-activating plant lectin, Viscum album agglutinin-I, induces apoptosis in human lymphocytes, monocytes, monocytic THP-1 cells and murine thymocytes Nat Immun 15 1996 295 311
5. B. Möckel, T. Schwarz, and H. Zinke Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells Arzneim Forsch 47(II)10 1997 1145 1151
6. H. Bantel, I. Engels, and W. Voelter Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis Cancer Res 59 1999 2083 2090
7. M. Langer, B. Möckel, and J. Eck Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis Biochem Biophys Res Commun 264 1999 944 948
8. Y. Endo, K. Tsurugi, and H. Franz The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. The RNA N-glycosidase activity of the protein FEBS Lett 231 1988 378 380
9. J. Eck, M. Langer, and B. Möckel Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain Eur J Biochem 264 1999 775 784
10. J. Eck, M. Langer, and B. Möckel Characterization of recombinant and plant-derived mistletoe lectin and their B-chains Eur J Biochem 265 1999 788 797
11. J. Beuth, H.L. Ko, and H.J. Gabius Behaviour of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside specific lectin from mistletoe in breast cancer patients Clin Invest 49 1992 658 661
12. J. Kleijnen, and P. Knipshild Mistletoe treatment for cancer. Review of controlled trials in humans Phytomedicine 1 1994 255 260
13. G.S. Kienle, F. Berrino, and A. Bussing Mistletoe in cancer - a systematic review on controlled trials Eur J Med Rex 8 3 2003 109 119
14. J. Weis, H.H. Bartsch, and F. Hennies Complementary medicine in cancer patients: demand, patients' attitudes and psychological beliefs Onkologie 21 1998 144 149
15. E. Ernst, and B. Cassileth How useful are unconventional cancer treatments? Eur J Cancer 35 1999 1608 1613
16. T. Hajto, K. Hostanska, and K. Weber Effect of recombinant lectin Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo Nat Immun 16 1998 34 46
17. P. Schöffski, S. Riggert, and P. Fumoleau Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European organization for research and treatment of cancer new drug development group Ann Oncol 15 2004 1816 1824
18. U. Schumacher, S. Feldhaus, and U. Mengs Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice Cancer Lett 150 2000 171 175
19. B. Schaffrath, U. Mengs, and T. Schwarz Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice Anticancer Res 21 2001 3981 3988
20. K. Hostanska, V. Vuong, and S. Rocha Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation Br J Can 88 2003 1785 1792
21. J. Müthing, M. Burg, and B. Möckel Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated gangliosides Glycobiology 12 8 2002 485 497
22. J. Müthing, I. Meisen, and P. Bulau Mistletoe lecting I is a sialic acid-specific lectin with strict preference to gangliosides with terminal neu5 Acα2-6Galβ1-4GlcNAc residues Biochemistry 43 2004 2996 3007
23. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 206
24. M. Adler, M. Langer, and K. Witthohn Detection of rViscumin in plasma samples by immuno-PCR Biochem Biophys Res Comm 300 2003 757 763